The conversation about mixing and matching vaccine types isn’t new but it’s still very important! With vaccine distribution problems and regional vaccine shortages across the globe, the topic of getting one dose of an mRNA-based vaccine and another dose of an Ad-based vaccine, remains pivotal. In this particular publication (The Lancet, August 12th), the immunogenicity and reactogenicity of heterologous vaccination with ChAdOx1 nCov-19 (Oxford/AstraZeneca) and BNT162b2 (Pfizer/BioNTech) is discussed.
Heterologous Groups:
A) BNT162b2 – BNT162b2 (3 week interval)
B) ChAdOx1 nCov-19 – ChAdOx1 nCov-19 (10-12 week interval)
C) ChAdOx1 nCov019 – BNT162b2 (10-12 week interval)
N = 138, conducted in Germany
Overall, it was found that heterologous vaccination was well tolerated and highly effective.